TORONTO, Nov. 29, 2019
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the
"Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated
cannabis leader with core operations in Latin America, today announced that
Sidney Himmel has resigned as
Director and Chair of the Board to pursue other interests,
effective immediately.
"On behalf of my fellow directors, the Company's management
team, and shareholders we thank Sid for his many contributions to
Khiron since its founding," said Alvaro
Torres, Khiron's CEO and Director. "Drawing on a wealth of
experience over a long and successful business career, Sid helped
Khiron grow in just three years from formation into one of the
leading cannabis companies in Latin
America. We are grateful for his contributions and wish him
all the best going forward."
Khiron's Board of Directors has appointed CEO Alvaro Torres as Interim Board Chair until a new
independent director is appointed to fill the vacancy created by
Mr. Himmel's resignation. In addition, Khiron's Board of
Directors has appointed Deborah
Rosati, FCPA, FCA, ICD.D, to replace Mr. Himmel as Chair of
the Audit Committee. As previously noted in the announcement
of Ms. Rosati's appointment to the Board of Directors of Khiron on
November 4, 2019, Ms. Rosati brings a
wealth of audit experience including positions as Vice Chair &
Chair of the Audit Committee at cannabis authority Lift & Co
(TSXV: LIFT), past Chair of the Audit Committee at Sears Canada
Inc., a Member of the Department Audit Committee at Correction
Services Canada, and at NexJ Systems Inc. where she was a Board
member and Chair of the Audit Committee.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-chairman-transition-and-appointment-of-audit-committee-chair-300966921.html
SOURCE Khiron Life Sciences Corp.